AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15974555 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study 11890972 — intervention group
Group type: COMPARATOR
Intervention: 27 degrees C (thermoneutral zone)
Number of subjects: 3
Study 10503585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (25 mg for 2 weeks, 50 mg for 2 weeks, and 100 mg for 4 weeks)
Number of subjects: 31
Study 10503585 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (taken once daily)
Number of subjects: 31
Study 8941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (1.2 x 10(6) IU/m2)
Number of subjects: 17
Study 8941876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2 (1.2 x 10(7) IU/m2)
Number of subjects: 17
Study 8941876 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant IL-2
Number of subjects: 17
Study 2010875 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis treatment including cranial irradiation and intrathecal methotrexate
Number of subjects: 0
Study 2010875 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis treatment including only intrathecal methotrexate and intermediate dose infusions of methotrexate
Number of subjects: 0
Study 2010875 — intervention group
Group type: COMPARATOR
Intervention: Learning disabled (LD) children
Number of subjects: 0
Study 2010875 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemic children
Number of subjects: 0
Study 7023527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release aminophylline
Number of subjects: 9
Study 7023527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31009405 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic Fecal Microbiota Transfer (FMT)
Number of subjects: 17
Study 31009405 — intervention group
Group type: COMPARATOR
Intervention: Autologous Fecal Microbiota Transfer (FMT)
Number of subjects: 17
Study 29177031 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Training Program (CSTP), 16 sessions
Number of subjects: 0
Study 29177031 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Training Program (CSTP)
Number of subjects: 0
Study 26391365 — intervention group
Group type: EXPERIMENTAL
Intervention: High pump speed setting
Number of subjects: 10
Study 26391365 — intervention group
Group type: COMPARATOR
Intervention: Low pump speed setting
Number of subjects: 10
Study 24042304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic recovery (FiO2 = 1.00)
Number of subjects: 8
Study 24042304 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic recovery (FiO2 ∼ 0.165)
Number of subjects: 8
Study 24042304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic recovery
Number of subjects: 8
Study 22734028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 1378
Study 22734028 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1378
Study 19957798 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 19957798 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 0
Study 19957798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate + Leflunomide (MTX + LEF)
Number of subjects: 0
Study 19957798 — intervention group
Group type: COMPARATOR
Intervention: MTX + LEF
Number of subjects: 0
Study 19957798 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study 19957798 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MTX, LEF, MTX + LEF)
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal glycemic control (HbA1c below 7.0%) in normoalbuminuric patients
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control below 130/80 mmHg in normoalbuminuric patients
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control (HbA1c below 7.0%) in microalbuminuric patients
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control below 130/80 mmHg in microalbuminuric patients
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of RAAS (ACE-I or ARB)
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I in type 1 diabetes
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB in type 2 diabetes
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial therapeutic approach (glycemic control, antihypertensive therapy, RAAS inhibition, statins, aspirin)
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal blood pressure levels < 130/80 mmHg for proteinuria < 1 g/day
Number of subjects: 0
Study 17922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal blood pressure levels < 120/75 mmHg for proteinuria ≥ 1 g/day
Number of subjects: 0
Study 15781600 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational program (10 weekly sessions)
Number of subjects: 82
Study 15781600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 82
Study 11981724 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (90 mg/kg per day)
Number of subjects: 0
Study 11981724 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 11981724 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated, healthy subjects)
Number of subjects: 0
Study 9609359 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol nicotinate 300 mg tds after meals for 3 months
Number of subjects: 13
Study 8553592 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril monotherapy
Number of subjects: 171
Study 8553592 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril + Bopindolol
Number of subjects: 171
Study 8553592 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril + Hydrochlorothiazide
Number of subjects: 171
Study 8553592 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (all groups)
Number of subjects: 171
Study 8553592 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 171
Study 2797894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of cefamandole at induction of anaesthesia and 750 mg every six hours during 24 hours after surgery
Number of subjects: 122
Study 2797894 — intervention group
Group type: COMPARATOR
Intervention: Single injection of 1.5 g of cefamandole at induction of anaesthesia
Number of subjects: 122
Study 381229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg ascorbic acid daily
Number of subjects: 24
Study 381229 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 mg ascorbic acid daily
Number of subjects: 24
Study 381229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30709437 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLG plus standard GVHD prophylaxis (ciclosporin and short-term methotrexate)
Number of subjects: 155
Study 30069600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (20 mg/day) plus HMG (150 or 225 IU)
Number of subjects: 251
Study 30069600 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 251
Study 27300114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen
Number of subjects: 102
Study 27300114 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (before HT)
Number of subjects: 102
Study 27300114 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (after 48 months of treatment)
Number of subjects: 102
Study 25112084 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui (GV 20), Sishencong (EX‐HN 1), Neiguan (PC 6), Zusanli (ST 36), and Hegu (LI 4) for 20 minutes, twice a week for 10 treatments.
Number of subjects: 60
Study 25112084 — intervention group
Group type: COMPARATOR
Intervention: Delayed acupuncture (no treatment during observation stage).
Number of subjects: 60
Study 22192643 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg (single dose)
Number of subjects: 18
Study 22192643 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg (multiple dose, once-daily for 9 days)
Number of subjects: 18
Study 22192643 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg (single and multiple doses)
Number of subjects: 18
Study 19154523 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids, vitamin C and Zn supplementation
Number of subjects: 60
Study 17614302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus trastuzumab
Number of subjects: 81
Study 17614302 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane plus trastuzumab
Number of subjects: 81
Study 15474698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 450
Study 15474698 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 450
Study 11793614 — intervention group
Group type: EXPERIMENTAL
Intervention: cilomilast 15 mg twice daily
Number of subjects: 36
Study 11793614 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 9745987 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg), administered 2 hr before habitual bedtime
Number of subjects: 10
Study 9745987 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 7973770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine)
Number of subjects: 0
Study 7973770 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin
Number of subjects: 0
Study 7973770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 0
Study 2467328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fibre diet during and after first cycle of cisplatin and vinblastine chemotherapy (Group 1)
Number of subjects: 55
Study 2467328 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine (Group 2)
Number of subjects: 55
Study 2467328 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) instead of vinblastine (Group 3)
Number of subjects: 55
Study 31027081 — intervention group
Group type: EXPERIMENTAL
Intervention: PHILOS plate with custom neutral-position shoulder and elbow sling for 30 days after surgery
Number of subjects: 112
Study 31027081 — intervention group
Group type: COMPARATOR
Intervention: PHILOS plate alone
Number of subjects: 112
Study 29722943 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate Pills (TUP)
Number of subjects: 82
Study 29722943 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintaining glucose- and lipid-reducing therapies)
Number of subjects: 82
Study 26226091 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help CBT-I with telephone support
Number of subjects: 207
Study 26226091 — intervention group
Group type: COMPARATOR
Intervention: self-help CBT-I
Number of subjects: 207
Study 24141628 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg orally once daily
Number of subjects: 1199
Study 24141628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 21358317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 40
Study 21358317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 0.9%)
Number of subjects: 40
Study 18285378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimented feeding regimen from birth to 34 weeks' postmenstrual age (PMA)
Number of subjects: 109
Study 18285378 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding regimen from birth to 34 weeks' postmenstrual age (PMA)
Number of subjects: 109
Study 16957145 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 761
Study 16957145 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 761
Study 16957145 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (Control)
Number of subjects: 761
Study 12859309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 12
Study 12859309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5 mg/kg
Number of subjects: 12
Study 12859309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Saline)
Number of subjects: 12
Study 16159930 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot GH (n = 51)
Number of subjects: 135
Study 16159930 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily GH (n = 53)
Number of subjects: 135
Study 16159930 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 31)
Number of subjects: 135
Study 10344296 — intervention group
Group type: COMPARATOR
Intervention: CHX (0.00025% chlorhexidine acetate)
Number of subjects: 19
Study 10344296 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+EDG (0.00025% chlorhexidine acetate with 0.005% ethyl‐6‐O‐decanoyl‐glucoside)
Number of subjects: 19
Study 8568292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 21
Study 1779084 — intervention group
Group type: EXPERIMENTAL
Intervention: Active based cream F14001
Number of subjects: 0
Study 1779084 — intervention group
Group type: COMPARATOR
Intervention: Placebo non-active based cream
Number of subjects: 0
Study 6111331 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg betaxolol
Number of subjects: 5
Study 6111331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6111331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg atenolol
Number of subjects: 5
Study 6111331 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg propranolol
Number of subjects: 5
Study 6111331 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg oxprenolol
Number of subjects: 5
Study 6111331 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sotalol
Number of subjects: 5
Study 31122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal triple antiretroviral treatment throughout both ante‐partum and post‐partum phases
Number of subjects: 861
Study 31122797 — intervention group
Group type: COMPARATOR
Intervention: Maternal non-adherence to triple antiretroviral treatment
Number of subjects: 861
Study 31122797 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal triple antiretroviral treatment
Number of subjects: 861
Study 31122797 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed and uninfected children
Number of subjects: 861
Study 26024922 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting bonuses
Number of subjects: 485
Study 26024922 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exclusion
Number of subjects: 485
Study 26024922 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-limitation
Number of subjects: 485
Study 26024922 — intervention group
Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 485
Study 26024922 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 485
Study 24267180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet enriched with milk minerals (MM group)
Number of subjects: 33
Study 24267180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet enriched with milk minerals (MM period)
Number of subjects: 33
Study 24267180 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 33
Study 24267180 — intervention group
Group type: COMPARATOR
Intervention: Control period (regular diet)
Number of subjects: 33
Study 21937519 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (Group 1, n = 18)
Number of subjects: 50
Study 21937519 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic with strength training (Group 2, n = 18)
Number of subjects: 50
Study 21937519 — intervention group
Group type: COMPARATOR
Intervention: Untrained (Group 3, n = 14)
Number of subjects: 50
Study 19116943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 40
Study 19116943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17170562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 414
Study 15147224 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time school nurses (5 days/week)
Number of subjects: 14
Study 15147224 — intervention group
Group type: COMPARATOR
Intervention: Part-time school nurses (2 days/week)
Number of subjects: 14
Study 11824107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic appendectomy with invaginant technic during cesarean section
Number of subjects: 59
Study 11824107 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section only
Number of subjects: 59
Study 10193231 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 microgram.kg‐1
Number of subjects: 80
Study 10193231 — intervention group
Group type: COMPARATOR
Intervention: saline placebo (control)
Number of subjects: 80
Study 8070935 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B alone (0.5 mg/kg/day; n = 14)
Number of subjects: 28
Study 8070935 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.5 mg/kg/day) plus 5-flucytosine (150 mg/kg/day; n = 14)
Number of subjects: 28
Study 8070935 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B alone
Number of subjects: 28
Study 8070935 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B plus 5-flucytosine
Number of subjects: 28
Study 31469593 — intervention group
Group type: COMPARATOR
Intervention: Hyrax (H)
Number of subjects: 75
Study 31469593 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix (QH)
Number of subjects: 75
Study 31469593 — intervention group
Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 75
Study 31561960 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (0.125-0.75 mg/kg/day)
Number of subjects: 34
Study 31561960 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (0.75 mg/kg/day)
Number of subjects: 34
Study 28006725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 100
Study 28006725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26619915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training using expression morph sequences for happy expressions
Number of subjects: 0
Study 26619915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training using expression morph sequences for fearful expressions
Number of subjects: 0
Study 23853246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m2 (3‐hour infusion) every 3 weeks for four cycles
Number of subjects: 295
Study 23853246 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 (1‐hour infusion) for 12 weeks
Number of subjects: 295
Study 23853246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 295
Study 23853246 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 295
Study 23853246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ixabepilone and paclitaxel
Number of subjects: 295
Study 21214498 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management system utilizing e-PHR, including secure messaging, self-monitoring, self-management of MS symptoms, and communication about upcoming clinic visits.
Number of subjects: 206
Study 21214498 — intervention group
Group type: COMPARATOR
Intervention: Usual care (secure Web-based messaging system)
Number of subjects: 206
Study 18290863 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy treatment
Number of subjects: 30
Study 18290863 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (Control)
Number of subjects: 30
Study 16817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased whole acupuncture therapy
Number of subjects: 113
Study 16817265 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 113
Study 12923621 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine (20 g/l)
Number of subjects: 363
Study 12923621 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous and isojoulic solution)
Number of subjects: 363
Study 11203620 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar attachment system
Number of subjects: 26
Study 11203620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachment system
Number of subjects: 26
Study 11203620 — intervention group
Group type: COMPARATOR
Intervention: Both bar and ball attachment systems
Number of subjects: 26
Study 8959854 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM 125
Number of subjects: 70
Study 8959854 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 70
Study 8237969 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3 g of calcium carbonate daily)
Number of subjects: 68
Study 8237969 — intervention group
Group type: COMPARATOR
Intervention: Sucrose placebo
Number of subjects: 68
Study 3815460 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (100 micrograms daily for nine weeks)
Number of subjects: 40
Study 3815460 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 3815460 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (after switching from placebo)
Number of subjects: 40
Study 3815460 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (after switching from interferon)
Number of subjects: 40
Study 29555213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits and physical activity assessment using Food Frequency Questionnaire (FFQ) and Physical Activity Scale (PAS)
Number of subjects: 428
Study 29555213 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity assessment
Number of subjects: 428
Study 29555213 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 428
Study 29555213 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of negative symptoms with dietary quality and physical activity
Number of subjects: 428